Marrone Bio Innovations (NASDAQ:MBII) Stock Crosses Below 50-Day Moving Average of $1.57

Marrone Bio Innovations Inc (NASDAQ:MBII) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.57 and traded as low as $1.43. Marrone Bio Innovations shares last traded at $1.45, with a volume of 600 shares trading hands.

Separately, National Securities reissued a “buy” rating and set a $2.50 price target on shares of Marrone Bio Innovations in a report on Friday, May 10th.

The company has a quick ratio of 1.47, a current ratio of 1.94 and a debt-to-equity ratio of 2.47. The firm’s fifty day simple moving average is $1.57.

Marrone Bio Innovations (NASDAQ:MBII) last announced its earnings results on Thursday, May 9th. The basic materials company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Marrone Bio Innovations had a negative return on equity of 123.95% and a negative net margin of 82.82%. The business had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.18 million. On average, research analysts anticipate that Marrone Bio Innovations Inc will post -0.16 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in MBII. Vanguard Group Inc. lifted its stake in Marrone Bio Innovations by 13.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,554,605 shares of the basic materials company’s stock worth $4,675,000 after acquiring an additional 303,201 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Marrone Bio Innovations in the 4th quarter worth approximately $73,000. SG Americas Securities LLC purchased a new position in shares of Marrone Bio Innovations in the 1st quarter worth approximately $74,000. Spark Investment Management LLC boosted its stake in shares of Marrone Bio Innovations by 47.5% in the 1st quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock worth $145,000 after buying an additional 30,600 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Marrone Bio Innovations by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock worth $652,000 after buying an additional 24,460 shares during the last quarter. 42.04% of the stock is owned by institutional investors and hedge funds.

Marrone Bio Innovations Company Profile (NASDAQ:MBII)

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

Featured Story: What is a Call Option?

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.